1. Home
  2. |Professionals
  3. |Charlene Sun

Charlene Sun

Counsel | She/Her/Hers
Counsel | She/Her/Hers
Y3N1bkBjcm93ZWxsLmNvbQ==
VCardLinkedIn
VCardLinkedIn

Areas of Focus

Overview

Charlene Sun is a counsel in Crowell & Moring’s Orange County office and is a member of the firm’s Antitrust and Competition Group. Charlene's practice involves counseling clients across a number of industries on a wide range of antitrust transactional and litigation matters. Charlene has provided strategic counsel with identifying and coordinating foreign merger control filings, compliance with the Hart-Scott-Rodino Act, and evaluating and advising on competitive issues associated with mergers, acquisitions, and competitor collaborations. She has also represented Fortune 500 companies as plaintiffs in antitrust recovery actions.

While Charlene was in law school, she served as an editor of the UC Irvine Law Review. She participated in various pro bono projects, which included work on cases concerning asylum, bankruptcy, and domestic violence.

Charlene serves as co-chair of the LGBTQ+ Affinity group, where she focuses on promoting equity, inclusion, and opportunity within the firm.

Career & Education

    • Chapman University, B.S., business administration, 2015
    • University of California, Irvine School of Law, J.D., magna cum laude, 2019
    • Chapman University, B.S., business administration, 2015
    • University of California, Irvine School of Law, J.D., magna cum laude, 2019

    • California
    • Minnesota
    • California
    • Minnesota

Charlene's Insights

Client Alert | 7 min read | 06.26.26

Federal Roundup: Updates for PBMs and Medicare Advantage Organizations

In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future....

View All Insights

Insights

Client Alert | 7 min read | 06.26.26

Federal Roundup: Updates for PBMs and Medicare Advantage Organizations

Client Alert | 3 min read | 02.24.26

State-Level Merger Control Grows: California Joins “Mini-HSR” Trend with Senate Bill 25

Firm News | 2 min read | 09.30.25

OCCDL Recognizes Crowell & Moring Lawyers at 2025 Awards Gala

Blog Post | 07.03.25

FTC Orders Divestitures in Retail Fuel Outlet Deal and Signals a Return to More Standard Remedy Discussions

View All Insights

Practices

Charlene's Insights

Client Alert | 7 min read | 06.26.26

Federal Roundup: Updates for PBMs and Medicare Advantage Organizations

In June 2026, federal regulators and lawmakers continued their efforts to improve drug affordability through targeted reforms. These recent developments will primarily impact pharmaceutical manufacturers, managed care organizations, and pharmacy benefit managers (PBM) serving Medicare Part D program members. PBMs, Medicare Advantage organizations, and Part D sponsors should monitor these changes in the interest of maintaining compliance and providing input on regulatory proposals that may influence their business operations or compensation structures in the future....

View All Insights